KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Thermo Fisher Scientific (TMO) Receivables - Other (2018 - 2026)

Thermo Fisher Scientific filings provide 9 years of Receivables - Other readings, the most recent being $1.7 billion for Q1 2026.

  • On a quarterly basis, Receivables - Other rose 23.28% to $1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 billion, a 23.28% increase, with the full-year FY2025 number at $1.7 billion, up 16.1% from a year prior.
  • Receivables - Other hit $1.7 billion in Q1 2026 for Thermo Fisher Scientific, up from $1.7 billion in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.7 billion in Q1 2026 to a low of $1.1 billion in Q2 2022.
  • Median Receivables - Other over the past 5 years was $1.4 billion (2025), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Receivables - Other: surged 54.46% in 2022 and later dropped 3.94% in 2025.
  • Thermo Fisher Scientific's Receivables - Other stood at $1.3 billion in 2022, then grew by 9.98% to $1.4 billion in 2023, then decreased by 0.55% to $1.4 billion in 2024, then rose by 16.1% to $1.7 billion in 2025, then grew by 1.08% to $1.7 billion in 2026.
  • The last three reported values for Receivables - Other were $1.7 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.6 billion (Q3 2025) per Business Quant data.